Terms: = Prostate cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
24 results:
1. Dynamics of cxcr4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
Klusa D; Lohaus F; Franken A; Baumbach M; Cojoc M; Dowling P; Linge A; Offermann A; Löck S; Hušman D; Rivandi M; Polzer B; Freytag V; Lange T; Neubauer H; Kücken M; Perner S; Hölscher T; Dubrovska A; Krause M; Kurth I; Baumann M; Peitzsch C
Int J Cancer; 2023 Jun; 152(12):2639-2654. PubMed ID: 36733230
[TBL] [Abstract] [Full Text] [Related]
2. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
3. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
4. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
[TBL] [Abstract] [Full Text] [Related]
5. Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma.
Floranović MP; Veličković LJ
Clin Genitourin Cancer; 2020 Aug; 18(4):e337-e342. PubMed ID: 31882334
[TBL] [Abstract] [Full Text] [Related]
6. The Expression of the Chemokine CXCL14 Correlates with Several Aggressive Aspects of Glioblastoma and Promotes Key Properties of Glioblastoma Cells.
Fazi B; Proserpio C; Galardi S; Annesi F; Cola M; Mangiola A; Michienzi A; Ciafrè SA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117166
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA UCA1 acts as a sponge of miR-204 to up-regulate cxcr4 expression and promote prostate cancer progression.
He C; Lu X; Yang F; Qin L; Guo Z; Sun Y; Wu J
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30940776
[TBL] [Abstract] [Full Text] [Related]
8. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
9. The Natural Compound Myricetin Effectively Represses the Malignant Progression of prostate cancer by Inhibiting PIM1 and Disrupting the PIM1/cxcr4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract] [Full Text] [Related]
10. Bioinformatic analyses reveal the key pathways and genes in the cxcr4 mediated mesenchymal subtype of glioblastoma.
Yi L; Tong L; Li T; Hai L; Abeysekera IR; Tao Z; Ma H; Liu P; Xie Y; Li J; Yuan F; Yu S; Yang X
Mol Med Rep; 2018 Jul; 18(1):741-748. PubMed ID: 29767255
[TBL] [Abstract] [Full Text] [Related]
11. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.
Bakkar A; Alshalalfa M; Petersen LF; Abou-Ouf H; Al-Mami A; Hegazy SA; Feng F; Alhajj R; Bijian K; Alaoui-Jamali MA; Bismar TA
Mol Biol Rep; 2016 Apr; 43(4):229-40. PubMed ID: 26907180
[TBL] [Abstract] [Full Text] [Related]
12. The association of cxcr4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract] [Full Text] [Related]
13. Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer.
Luo Y; Jiang QW; Wu JY; Qiu JG; Zhang WJ; Mei XL; Shi Z; Di JM
Oncotarget; 2015 Sep; 6(26):22564-74. PubMed ID: 26087186
[TBL] [Abstract] [Full Text] [Related]
14. cxcr4 over-expression and survival in cancer: a system review and meta-analysis.
Zhao H; Guo L; Zhao H; Zhao J; Weng H; Zhao B
Oncotarget; 2015 Mar; 6(7):5022-40. PubMed ID: 25669980
[TBL] [Abstract] [Full Text] [Related]
15. CD117⁺ cells in the circulation are predictive of advanced prostate cancer.
Kerr BA; Miocinovic R; Smith AK; West XZ; Watts KE; Alzayed AW; Klink JC; Mir MC; Sturey T; Hansel DE; Heston WD; Stephenson AJ; Klein EA; Byzova TV
Oncotarget; 2015 Jan; 6(3):1889-97. PubMed ID: 25595903
[TBL] [Abstract] [Full Text] [Related]
16. Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells.
Labsch S; Liu L; Bauer N; Zhang Y; Aleksandrowicz E; Gladkich J; Schönsiegel F; Herr I
Int J Oncol; 2014 May; 44(5):1470-80. PubMed ID: 24626333
[TBL] [Abstract] [Full Text] [Related]
17. A differential role for cxcr4 in the regulation of normal versus malignant breast stem cell activity.
Ablett MP; O'Brien CS; Sims AH; Farnie G; Clarke RB
Oncotarget; 2014 Feb; 5(3):599-612. PubMed ID: 24583601
[TBL] [Abstract] [Full Text] [Related]
18. Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells.
Don-Salu-Hewage AS; Chan SY; McAndrews KM; Chetram MA; Dawson MR; Bethea DA; Hinton CV
PLoS One; 2013; 8(2):e57194. PubMed ID: 23468933
[TBL] [Abstract] [Full Text] [Related]
19. cxcr4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
[TBL] [Abstract] [Full Text] [Related]
20. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.
Shiozawa Y; Pienta KJ; Taichman RS
Clin Cancer Res; 2011 Sep; 17(17):5553-8. PubMed ID: 21676926
[TBL] [Abstract] [Full Text] [Related]
[Next]
